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Antidepressant withdrawal symptoms are well-recognised, but their potential duration remains 
uncertain.  
OBJECTIVE: 
We aimed to describe the characteristics of withdrawal associated with two popular classes of 
antidepressants, including duration.   
METHODS: 
We analysed the content of a sample of posts on an antidepressant withdrawal website. We 
compared the characteristics of withdrawal associated with SSRIs and SNRIs, including time of 
onset, duration and nature of symptoms. 
RESULTS: 
110 posts about SSRI withdrawal, and 63 concerning SNRI withdrawal, were analysed. The 
mean duration of withdrawal symptoms was significantly longer with SSRIs than SNRIs: 90.5 
weeks (standard deviation, SD, 150.0) and 50.8 weeks (SD 76.0) respectively; p=0.043). 
Neurological symptoms, such as ‘brain zaps,’ were more common among SNRI users 
(p=0.023). Psychosexual/genitourinary symptoms may be more common among SSRI users 
(p=0.054).  
LIMITATIONS: 
The website aims to help people with antidepressant withdrawal, and is therefore likely to attract 
people who have difficulties. Length of prior use of antidepressants was long, with a mean of 
252.2 weeks (SD 250.8).  
CONCLUSIONS: 
People accessing antidepressant withdrawal websites report experiencing protracted withdrawal 
symptoms. There are some differences in the characteristics of withdrawal associated with 
different classes of antidepressants.   
 




SSRI and SNRI withdrawal symptoms reported on an internet forum 
 
Introduction 
Antidepressant use is high and increasing. In 2012, 13% of the population of the United States 
were prescribed antidepressants, a figure that had almost doubled since the year 2000 [1]. The 
majority of these prescriptions were for antidepressants classified as SSRIs or SNRIs. There 
are similar trends across the world [2], with the number of prescriptions for antidepressants in 
the United Kingdom more than doubling since 2005 [3]. 
There is now clear evidence that a variety of symptoms can result from the discontinuation of all 
antidepressant classes [4]. They have been observed to be more common in drugs with a 
shorter half-life, such as venlafaxine and paroxetine, and if the antidepressant had been taken 
for eight weeks or longer before withdrawal [5]. Common symptoms following SSRI withdrawal 
include dizziness, nausea, fatigue, anxiety, headache, electric shock-like symptoms, sweating, 
insomnia and nightmares [6]. There is comparatively less research on SNRI withdrawal, 
however, and little data on the nature of the symptoms from the user’s perspective. 
Symptoms are most commonly reported after sudden cessation of the medication, but can also 
occur following gradual tapering of the dose [4]. The time of onset of withdrawal symptoms is 
currently considered to be within a few days of stopping or reducing the antidepressant [5,7]. 
Onset of withdrawal symptoms after a week is considered unusual [4].  
The length of time for which withdrawal symptoms can persist remains uncertain and somewhat 
controversial. Antidepressant users have been reporting the occurrence of protracted 
withdrawal states lasting months and even years, for some time [8]. However, patient 
information issued by professional organisations suggests that SSRI and SNRI withdrawal 
symptoms last for up to 6-8 weeks [9,7]. Some authors suggest that severe and prolonged 
withdrawal symptoms represent ‘medically unexplained symptoms’ and dispute that they have 
any relation to antidepressant discontinuation [10]. However, psychiatric literature has started to 
report cases with longer durations of symptoms [6,8].  
This study examines self-reports of SSRI and SNRI withdrawal symptoms by users of an online 
forum designed to help people withdraw from antidepressants. It aims to increase our 
knowledge about the characteristics of antidepressant withdrawal associated with these two 
popular classes of antidepressant, including the potential duration of symptoms.   
 
Method  
Self-reports of antidepressant withdrawal symptoms were found on 
http://survivingantidepressants.org/ [11]. This website advertises itself as offering ‘Peer support 
for [antidepressant] tapering and withdrawal syndrome’. The information for this study was 
found in the ‘Introduction’ area of the website, an online chatroom where individual users 
introduce themselves to the online community. Users are encouraged to include a variety of 
details in the signature area displayed for each of their posts. This typically contains a 
medication history, including antidepressant names, doses, durations of use and dates of 
changes; and details and dates of withdrawal symptoms. The structure of this introductory 
section ensures that each post is associated with a unique antidepressant user.  
 
A sample of posts was selected by collecting, in chronological order, posts in which the 
presence of withdrawal symptoms was reported, the medication being stopped or already 
ceased was clearly identified, and the withdrawal symptoms adequately described for the 
purposes of this study. For this study, posts involving withdrawal from SSRIs or SNRIs were 
selected, with subtypes of SSRIs and SNRIs grouped together. Posts in which authors were on 
multiple psychotropic medications and were unsure which was causing their symptoms were 
excluded. One post where it appeared the author had used an SSRI and SNRI antidepressant 
simultaneously was excluded.  
 
Each selected website user’s withdrawal symptoms were listed, verbatim. These were manually 
ascribed to one of 8 symptom groups (neurological, psychological, gastrointestinal, 
musculoskeletal, respiratory, psychosexual/genitourinary, and other). The proportion of all users 
who experienced at least one of each class of symptom was computed and compared between 
drug types, along with the average number of symptoms within each symptom group 
experienced per person.  
 
The reported duration of onset of withdrawal symptoms after medication reduction, the duration 
of withdrawal symptoms themselves, the mean duration of prior treatment and mean length of 
taper were all calculated for those people taking SSRIs and SNRIs, using the available data. 
Differences between groups were explored using non-parametric tests, due to the skewed 
nature of distributions. 
Results 
 
The sample consisted of posts by 174 individuals who had been taking SSRIs or SNRIs. 110 
people reported withdrawal symptoms following SSRI use, specifically fluoxetine (N=9), 
escitalopram (N=35), sertraline (N=23), paroxetine (N=24) and citalopram (N=19). 63 people 
reported withdrawal symptoms following SNRI use, specifically venlafaxine (N=50) and 
duloxetine (N=13). 
 
There was no statistically significant difference between mean durations of prior treatment or 
mean lengths of taper in the SSRI and SNRI groups. The combined mean length of prior 
treatment was 252.2 weeks (standard deviation, SD, 250.8; N=146); the median was 156.0 
(interquartile range, IQR, 50-416). Combined mean length of taper was 16.6 weeks (SD 25.9; 
median 4.0, IQR 0-20.0; N=79).  
 
The mean time to onset of withdrawal symptoms following SSRI discontinuation or reduction 
(4.5 weeks, SD 13.0; median 1.3, IQR 0-6.0; N=66) appeared longer than for SNRIs (1.5 weeks, 
SD 3.0; median 0.3, IQR 0-1.3; N=46), however this difference did not reach statistical 
significance (t=1.51; p=0.13). The combined mean time to onset was 3.3 weeks (SD 10.2; 
median 1.0, IQR 0-3.4).   
 
Withdrawal symptoms lasted significantly longer for those taking SSRIs than SNRIs. The mean 
duration of withdrawal symptoms in the SSRI group was 90.5 weeks (SD 150.0; median 34.0, 
IQR 8.0-104.0; N=97), and in the SNRI group 50.8 weeks (SD 76.0; median 28.0, IQR 4.5-62.8; 
N=40); t=2.05, p=0.043.  
 
The duration of symptoms positively correlated with length of taper (R2=0.258, p=0.038; N=65), 
but not with duration of previous treatment. Time to onset of symptoms was not associated with 
either.  
 
Table 1 shows numbers and proportions of users experiencing at least one symptom in each 
class of withdrawal symptoms. The most common types of symptom in both the SSRI and SNRI 
groups were psychological, followed in descending frequency by neurological, gastrointestinal, 
musculoskeletal, and cardiovascular symptoms. Neurological effects were significantly more 
common among people who had withdrawn from SNRIs. There was a trend towards sexual and 
genitourinary effects being more frequent in people withdrawing from SSRIs; however, this 
difference did not reach statistical significance.  
 INSERT TABLE 1 HERE 
 
Users’ descriptions of neurological and psychological symptoms indicate experiences that are 
hard to classify using standard medical technology. Some, such as ‘brain zaps’ and electric 
shock-like sensations, have been noted before, but some are less familiar, such as ‘brain 




The data suggest that some people experience protracted withdrawal symptoms following both 
SSRI and SNRI withdrawal. The average duration of withdrawal symptoms among SSRI users 
was almost 21 months, and for SNRI users it was nearly 12 months. Among SSRI users, 50% 
experienced symptoms lasting 7.8 months or more, and for 25% symptoms lasted at least 2 
years. For 50% of SNRI users, symptoms lasted at least 6.4 months, and for 25% they lasted 
for 14.4 months or more. 
Reported time before onset of withdrawal symptoms was also longer than previously 
documented for people withdrawing from SSRIs/SNRIs. For 50% of SSRI users this was almost 
9 days or more, and for 25% of users it exceeded 6 weeks. For those taking SNRIs it was closer 
to the duration previously reported, which likely reflects the short action of venlafaxine, the most 
commonly used agent in this group.   
 
The positive correlation between duration of symptoms and length of taper is likely to indicate 
that people experiencing difficult and protracted withdrawal symptoms reduce their 
antidepressants more slowly.  
 The prominence of psychological, neurological and gastrointestinal symptoms is consistent with 
the previous literature on SSRI and SNRI withdrawal [4], and lends this study face validity. The 
findings of higher rates of neurological symptoms with SNRI withdrawal, as well as the trend 
towards higher rates of psychosexual/genitourinary symptoms with SSRIs, have not been 
documented before and are likely to reflect the different pharmacological profiles of the different 
classes of antidepressant. 
 
The verbatim description of symptoms revealed some unusual examples, not previously 
documented in the literature. The language used vividly illustrates the sometimes bizarre and 




This study has a number of limitations. Most importantly, the website used was specifically 
designed to help people withdraw from antidepressants, and as such is likely to attract users 
who have had particular difficulties with the process of withdrawal. Moreover, the users of the 
site had used antidepressants for long periods, and results are likely to reflect this long duration 
of prior use.  
 
The study does not, therefore, represent a prevalence study of occurrence of withdrawal 
symptoms, and does not describe the characteristics of antidepressant withdrawal among all 
users. Nevertheless, given the frequency of antidepressant prescribing, it is important that these 
adverse experiences are described and that differences between commonly used agents are 
recognised. This is especially important in view of evidence that people are taking 
antidepressants for longer [12,13]. In 2011, 60% of antidepressant users in the US reported 
using them for more than 2 years [14].  
 
It is also possible that symptoms were misattributed, exaggerated or influenced by reports by 
other people, and that they might be associated with confounding factors such as use of other 
medication or the presence medical conditions. However, other research suggests that internet 
data can be used to provide reliable accounts of users’ experiences of drug-induced adverse 




Whilst its limitations should be borne in mind, this analysis of self-reported symptoms of SSRI 
and SNRI withdrawal highlights some important issues for clinical practice. The reported 
maximum duration of withdrawal symptoms was far in excess of the upper limit that is 
commonly quoted to patients, with both drug classes but particularly with SSRIs. Clinicians and 
patients need to be aware of this possibility when considering starting or stopping 
antidepressants.  
 
The study illustrates some differences between antidepressant classes in the nature of 
subjective symptoms of SSRI and SNRI withdrawal, and the sometimes idiosyncratic ways in 
which they are described by individual patients. Knowledge of such descriptors may aid 
clinicians in understanding unusual presentations after antidepressant discontinuation.  
  
Given the high and increasing rate of prescribing of antidepressants across western countries, 
this study suggests that further research into ways to alleviate prolonged adverse experiences 
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Table (1 in total) 
 
 
Table 1: Types of withdrawal symptoms 
 
 








% of people 
experiencing at least 










Dizziness, ‘brain zaps’*, ‘whoosh in ears’, ringing ears, 
paraesthesia, ‘needles under skin’, sensitive to light, buzzing sound, 
burning sensation, restless legs, ‘electric shocks’, leg spasm, 
tremors, balance problems, ‘tingly lips’, ‘blurry vision’, ‘vision lagging 










‘Brain fog’, anxiety, depression, feeling suicidal, irritable, feeling 
‘lousy’, ‘emotional numbness’, pessimism, loss of hope, ’ ‘emotional 
pain’, ‘inner torment’, anger, insomnia, obsessive thoughts, poor 
concentration and memory, panic, depersonalisation, paranoia, 
feeling ‘wired’, terrifying dreams, ‘vivid nonsensical dreams’, ‘out of 










Nausea, bloated, diarrhoea, constipation, acid reflux, stomach 









Palpitations, chest pain, racing heart, high blood pressure, chest 







































Recurring infections, bad skin, hives  
2.7 
 
3.2 
 
p=1.000 
